Latest News & Features
Big Pharma
Genomics company’s in-house attorney removed from case over links with patent infringement case | Court denied plaintiff’s motion to disqualify entire legal team. 7 November 2023
Americas
Appeals court faults lower court’s claim construction and its reliance on intrinsic evidence alone | Court emphasises that extrinsic evidence is needed in litigation over heart disease drug. 7 November 2023
Generics
District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor. 2 November 2023
Medtech
Precedential ruling finds errors in lower court’s findings in a case concerning medical devices | Earlier verdict has been vacated and remanded. 2 November 2023
Big Pharma
US Court of Appeals dismisses appeal due to a ‘lack of jurisdiction’ | Dispute against Jiangsu Hengrui Pharmaceuticals began as a patent suit but the discovery process prompted trade secret claims. 31 October 2023
Biotechnology
RSB Spine files patent infringement lawsuit against competitors over spinal implant products | Plaintiff claims the defendants had knowledge of patent infringement. 31 October 2023
Americas
Biopharmaceutical patent partner leads team of technical advisors and an associate in California | Partner experienced in patent prosecution, freedom-to-operate analysis, and assessing infringement validity in the pharma and biotech industry. 26 October 2023
Big Pharma
Swiss multinational says competitor has been “uncooperative” in investigation into whether former Novartis employee took trade secrets |Novartis files complaint for discovery, asking for permission to issue subpoena. 26 October 2023
Biotechnology
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction delays a generic's launch but the patent is invalidated or there is a finding of non-infringement. 26 October 2023
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills. 26 October 2023